Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
University of California, San Francisco · Broad Institute · +2 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
569
total citations
- FWCI
- 31.76
- Percentile
- 100%
- References
- 43
Citations per year
Authors
18Topics & keywords
Topics
Keywords
- Multiple sclerosis
- Medicine
- Placebo
- Clinical endpoint
- Dimethyl fumarate
- Adverse effect
- Internal medicine
- Crossover study
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.